 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The effect of multi-receptor tyrosine kinase inhibitor cabotinib as a single agent in the treatment of advanced soft tissue sarcoma

Clin Cancer Res: The effect of multi-receptor tyrosine kinase inhibitor cabotinib as a single agent in the treatment of advanced soft tissue sarcoma

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

pi 3 2

circulating tumor cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Soft tissue sarcoma (STS) is a rare heterogeneous mesenchymal tumor
.

For decades, the main treatment for advanced, unresectable soft tissue sarcoma has been palliative chemotherapy

This is a multicenter, open-label, single-arm Phase 2 trial that recruits adult patients with advanced soft tissue sarcoma who have received at least one standard systemic treatment and are treated with cabozantinib monotherapy, 60 mg/day, orally
.

The primary endpoints are overall response rate and 6-month progression-free survival (PFS)

Progression-free survival of patients with soft tissue sarcoma treated with cabozantinib

Among 54 evaluable patients, 6 (11.
1%) patients achieved objective remission (all were partial remissions)
.

After a median of 4 courses of treatment, the 6-month progression-free survival rate was 49.

Among 54 evaluable patients, 6 (11.

Changes of tumor size in two cases of soft tissue sarcoma before and after treatment

In summary, cabozantinib monotherapy has shown anti-tumor activity in some subtypes of soft tissue sarcoma (alveolar soft tissue sarcoma, undifferentiated pleomorphic sarcoma, extraosseous myxoid chondrosarcoma and leiomyosarcoma)

Cabozantinib monotherapy demonstrated a subtype in a portion of soft tissue sarcomas (alveolar soft tissue sarcoma, pleomorphic undifferentiated sarcoma, bone and outer myxoid chondrosarcoma leiomyosarcoma) Antitumor Cabozantinib monotherapy Some subtypes of soft tissue sarcoma (alveolar soft tissue sarcoma, undifferentiated pleomorphic sarcoma, extraosseous mucoid chondrosarcoma and leiomyosarcoma) showed anti-tumor activity

Original source:

O'Sullivan Coyne Geraldine,Kummar Shivaani,Hu James et al.

Clinical activity of single-agent cabozantinib ( XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft tissue sarcomas in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.